Ineffectiveness of tumour necrosis factor-alpha inhibition in association with bisphosphonates for the treatment of cherubism

Clinical and Experimental Rheumatology

Volumn 29, Issue 1, 2011, Pages 147-

  Pagnini, I ^a   Simonini, G ^a   Mortilla, M ^a   Giani, T ^a   Pascoli, L ^a   Cimaz, Rolando ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; BONE DENSITY CONSERVATION AGENT; MONOCLONAL ANTIBODY;

CASE REPORT; CHILD; CLINICAL EVALUATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; FIBROUS DYSPLASIA; HUMAN; JAW RADIOGRAPHY; LETTER; MALOCCLUSION; PHYSICAL EXAMINATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; TREATMENT DURATION; DRUG ANTAGONISM; RADIOGRAPHY; TREATMENT FAILURE;

ALENDRONATE; ANTIBODIES, MONOCLONAL; BONE DENSITY CONSERVATION AGENTS; CHERUBISM; CHILD, PRESCHOOL; FEMALE; HUMANS; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79955648483     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Letter

References (8)

1. UEKI Y, TIZIANI V, SANTANNA C et al.: Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism. Nat Genet 2001; 28: 125-6.
2. LI CY, YU SF: A novel mutation in the SH3BP2 gene causes cherubism: case report. BMC Med Genet 2006; 7: 84.
3. FERGUSON PJ, EL-SHANTI HI: Autoinflammatory bone disorders. Curr Opin Rheumatol 2007; 19: 492-8.
4. LIETMAN SA, YIN L, LEVINE MA: SH3BP2 is an activator of NFAT activity and osteoclastogenesis. Biochem Biophys Res Commun 2008; 371: 644-8.
5. UEKI Y, LIN CY, SENOO M et al.: Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice. Cell 2007; 128: 71-83.
6. ALIPRANTIS AO, UEKI Y, SULYANTO R et al.: NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J Clin Invest 2008; 118: 3775-89.
7. SOUTHGATE J, SARMA U, TOWNEND JV, BARRON J, FLANAGAN AM: Study of the cell biology and biochemistry of cherubism. J Clin Pathol 2008; 51: 831-7.
8. NOVACK DV, FACCIO R: Jawing about TNF: new hope for cherubism. Cell 2007; 128: 15-7.